Viracta Therapeutics Q4 2022 Earnings Report

Viracta Therapeutics EPS Results

• Actual EPS: -$0.27
• Consensus EPS: -$0.40
• Beat/Miss: Beat by +$0.13
• One Year Ago EPS: N/A

Viracta Therapeutics Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Viracta Therapeutics Announcement Details

• Quarter: Q4 2022
• Date: 3/13/2023
• Time: N/A

Viracta Therapeutics (NASDAQ:VIRX), a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide. Its lead product candidate is Nana-val, an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir. The company's Nana-val is in various ongoing clinical trials, including NAVAL-1, an open-label Phase 2 basket trial for the treatment of multiple subtypes of relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma, as well as an open-label Phase 1b/2 trial for the treatment of EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors. Its product pipeline also includes vecabrutinib, a clinical-stage product candidate; and VRx-510, a preclinical product candidate. The company is headquartered in Cardiff, California.